MarginsXMarginsX
Home › Markets › Health Care › ADXN

Addex Therapeutics Ltd (ADXN)

ADXN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.83
-5.67% on the day
Market cap
$6.5M
Nano cap
Revenue · 2025
$36K
-92.6% on 2024
Net income · 2025
-$8.0M
-22448.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1574232/000110465926062447/0001104659-26-062447-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from CHF at 0.8384 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerADXN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountrySwitzerland
IPO yearNot reported by the screener
SEC CIK0001574232
SEC industry codePharmaceutical Preparations
Incorporated inSwitzerland

Financials · 2025

LineValue
Revenue$36K
Net income-$8.0M
Operating income-$3.4M
Net margin-22448.4%
Operating margin-9390.8%
Revenue growth-92.6%
Cash$2.0M
Total assets$7.6M
P/E (computed)Net income was not positive
P/S (computed)182.5×

Reported in CHF; shown in US dollars.

Warning signs

Cash runway
9.1 months
1.6M CHF cash at December 31, 2025
Share count, 1 year
+15.2%
2024-12-31 to 2025-12-31 · +3733.1% over 3 years
Going-concern doubt
Yes
20-F filed May 15, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors individually and collectively indicate that a material uncertainty exists that raises substantial doubt about the Group's ability to continue as a going concern for one year from the date of issuance of these consolidated financial statements."
20-F 2026-05-15
Cash and burn1.6M CHF cash; operating cash flow -543K CHF a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-12-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO AG, Zurich, SwitzerlandPCAOB Form AP 2026-06-01
Late filings, 12 months1 NT noticeNT 20-F 2026-04-30
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
30K CHF-6.7M CHF-2.2M CHF1.6M CHF0 CHF30K CHF20-F 2026-05-15
FY 2024
2024-12-31
404K CHF7.1M CHF-5.4M CHF3.3M CHF0 CHF404K CHF20-F 2025-05-15
FY 2023
2023-12-31
1.6M CHF-10.6M CHF-8.0M CHF3.9M CHF0 CHF1.6M CHF20-F 2025-05-15
FY 2022
2022-12-31
1.4M CHF-20.8M CHF-16.4M CHF7.0M CHF0 CHF1.4M CHF20-F 2025-05-15
FY 2021
2021-12-31
2.9M CHF-15.4M CHF-14.7M CHF20.5M CHF0 CHF2.9M CHF20-F 2024-04-18
FY 2020
2020-12-31
3.6M CHF-12.9M CHF-12.2M CHF18.7M CHF0 CHF3.6M CHF20-F 2023-03-30
FY 2019
2019-12-31
2.8M CHF-14.8M CHF-9.5M CHF31.5M CHF0 CHF2.8M CHF20-F 2022-03-10
FY 2018
2018-12-31
6.0M CHF-1.6M CHF1.8M CHF31.5M CHF0 CHF6.0M CHF20-F 2021-03-11

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CHF.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-12-10
Latest annual report
FORM 20-F
20-F2026-05-15
Latest quarterly / interim
FORM 6-K
6-K2026-11-12

Source: SEC EDGAR submissions feed, 289 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+40.0%
1 month+34.9%
3 months-31.8%
Year to date-47.4%
1 year-52.8%
From 52-week high-54.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ENVBEnveric Biosciences Inc.$1.44-4.95%$6.4M
TOVXTheriva Biologics Inc.$0.1400-2.85%$6.4M
TCRTAlaunos Therapeutics Inc.$1.60-1.84%$6.7M
SNGXSoligenix Inc.$0.2882-10.22%$6.7M
TPSTTempest Therapeutics Inc.$0.3418-10.50%$6.8M
FBLGFibroBiologics Inc.$0.9034-2.00%$6.1M
XCURExicure Inc.$1.07-0.93%$7.0M
LGVNLongeveron Inc.$2.14-14.06%$7.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier